Nachweis von DPD-Exon-14-Skipping vor 5-Fluorouracil-Behandlung?

Literatur

• 1 Iyer L, Ratain M -J. 5-Fluorouracil pharmakokinetics: Causes for variability and strategies for modulation in cancer chemotherapy.  Cancer Invest. 1999;  17 494-506
• 2 Fleming R A. et al . Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.  Cancer Research. 1992;  52 2899-2902
• 3 Van Kuilenburg A BP. et al . Clinical implications if Dihydropyrimidine Dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.  Clin Cancer Res. 2000;  6 4705-4712
• 4 Raida M. et al . Prevalence of a Common Point Mutation in the Dihydropyrimidine Dehydrogenase (DPD) Gene within the 5‘-Splice Donor Site of Intron 14 in Patients with Severe 5-Fluorouracil (5-FU) Related Toxicity Compared to Controls.  Clin Cancer Res. 2001;  7 2832-2839

Autoren